Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnostic marker and platform for drug design in myocardial infarction and heart failure

A technology for myocardial infarction and heart disease, applied in the field of diagnostic markers and drug design platforms in myocardial infarction and heart failure, can solve problems such as reducing ejection fraction and increasing end-diastolic volume

Inactive Publication Date: 2010-02-10
公共健康研究中心
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, patients with high early MMP-9 levels had a significant risk of late-onset CHF (odds ratio 6.5, p<0.006) and left ventricular remodeling (reduced ejection fraction, increased end-diastolic volume)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic marker and platform for drug design in myocardial infarction and heart failure
  • Diagnostic marker and platform for drug design in myocardial infarction and heart failure
  • Diagnostic marker and platform for drug design in myocardial infarction and heart failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0156] Patients and methods

[0157] In order to increase our chances of detecting relevant SNPs in the context of ventricular remodeling, we selected two groups of patients with "extreme" phenotypes after myocardial infarction, that is, patients who developed very smoothly after infarction (EF> 55%, average 60%) and Patients with poor development (EF<40%, mean 29%). Each group contains 22 patients.

[0158] Genomic DNA was extracted from peripheral blood mononuclear cells after Ficoll was isolated. The extraction was performed using FlexiGene DNA kit (Qiagen) according to the manufacturer's instructions. The quantity and quality of DNA were evaluated using Nanodrop spectrophotometer. DNA integrity was assessed by agarose gel electrophoresis.

[0159] Without knowing the patient's phenotype, the entire MMP-9 gene was sequenced in all patients, including the promoter, coding sequence, and untranslated region (9kb in total).

[0160] The plasma MMP-9 level was determined by gelatin ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods for determining the susceptibility of an individual to a heart condition, post myocardial infarction, comprising detecting the presence of an amino acid change in the sequence of the hemopexindomain of MMP -9 (Matrix Metalloproteinase 9), the presence of an amino acid change in said domain being indicative of susceptibility to said heart condition, post myocardial infarction is described,together with methods for drug design.

Description

[0001] This application claims the priority of U.S. Provisional Application No. 60 / 884,979, so it is incorporated by reference. Invention field [0002] The invention relates to the application of diagnostic markers and a platform for drug design in myocardial infarction and heart failure. Background of the invention [0003] Congestive heart failure (CHF) is not a specific disease, but a collection of signs and symptoms (compilation), all of which are caused by the heart's inability to properly increase cardiac output as needed. Patients typically exhibit shortness of breath, edema, and fatigue. CHF has become an epidemic disease, affecting 3% of the adult population. The mortality rate of CHF is higher than that of many types of cancer, and its five-year survival is less than 30%. Myocardial infarction (MI) is one of the main causes of CHF. Left ventricular reconstruction greatly promotes CHF. [0004] It is now generally accepted that changes in the myocardial extracellular m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68
CPCC12Q2600/156C12Q2600/172C12Q2600/158C12Q1/6883C12Q2600/118C12Q2600/136Y10T436/143333A61P43/00A61P9/00A61P9/04A61P9/10
Inventor 丹尼尔·R·瓦格纳迪迪埃·鲁伊伊万·德沃
Owner 公共健康研究中心
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com